Molecular characteristics and clinical significance of KRAS wild-type pancreatic cancer tumors

I. Introduction

Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors of the digestive system, with a long-term 5-year survival rate below 10%. KRAS gene mutation is the earliest and most common driver event in PDAC development, occurring in approximately 90% of PDAC patients. Despite the dominant role of KRAS mutations in PDAC, about 5%-10% of patients have tumors without detectable KRAS mutations, classified as KRAS wild-type (KRAS-WT) PDAC. Due to limited case numbers, the molecular characteristics, driving mechanisms, and clinical behavior of KRAS-WT PDAC have lacked systematic study. With the widespread application of high-throughput sequencing technologies, increasing evidence suggests that KRAS-WT PDAC may represent a distinct molecular subtype, with tumorigenesis dependent on other driver gene alterations and potential heightened sensitivity to specific targeted or immunotherapies.

II. Molecular Characteristics of KRAS-WT PDAC

(1) Gene Mutation Profile

In KRAS-WT PDAC, the most common co-mutated gene is TP53, with a detection rate of 44.5%, significantly lower than in KRAS-mutant cases. BRAF mutations are the most characteristic targetable variants in the KRAS-WT group, with a detection rate of 13.0%, including BRAF V600E point mutations and non-V600E mutations. Other high-frequency mutations involve DNA damage repair pathways (BRCA2, ATM, BAP1, RAD50, FANCE, PALB2), chromatin remodeling pathways (ARID1A, PBRM1, ARID2, KMT2D, KMT2C, SMARCA4, SETD2), and cell cycle control pathways (CDKN2A, CCND1, CCNE1).

(2) Structural Variation Features

Beyond point mutations, KRAS-WT PDAC exhibits various targetable gene fusion events, including BRAF fusions (6.6%), FGFR2 fusions (5.2%), ALK fusions (2.6%), RET fusions (1.3%), and NRG1 fusions (1.3%). Oncogenic gene amplifications are also detected, such as FGF3 (3.0%), ERBB2 (2.2%), FGFR3 (1.8%), NTRK (1.8%), and MET (1.3%). These structural variations are rare in KRAS-mutant tumors, suggesting they may serve as alternative driver events in KRAS-WT PDAC.

(3) Immune Microenvironment Features

KRAS-WT and KRAS-mutant tumors show no significant difference in PD-L1 expression levels (15.8% vs. 17.0%). However, the KRAS-WT group has significantly higher rates of MSI-H (4.7% vs. 0.7%) and TMB-H (4.5% vs. 1.0%). Immune infiltration analysis reveals increased densities of CD8+ T cells, natural killer cells, and myeloid dendritic cells in KRAS-WT tumors, indicating an immunologically active microenvironment.

III. Survival Advantage in KRAS-WT Patients

Real-world survival data analysis demonstrates that KRAS-WT patients exhibit significantly better overall survival compared to KRAS-mutant patients. This survival advantage persists in subgroups receiving standard chemotherapy regimens (gemcitabine plus nab-paclitaxel or 5-FU plus oxaliplatin), suggesting KRAS status may serve as an independent prognostic factor.

IV. Discussion

(1) Molecular Heterogeneity and Driving Mechanisms of KRAS-WT PDAC

KRAS-WT PDAC is not a single disease entity but a molecularly heterogeneous group defined by alternative driver events. BRAF mutations are the most common alternative drivers, directly activating the MAPK pathway to mimic KRAS mutation effects. Additionally, fusion genes (FGFR, ALK, RET, NRG1) and amplified genes (ERBB2, MET, FGFR) serve as potential drivers, providing molecular bases for targeted therapies. Enrichment of DNA damage repair and chromatin remodeling pathway mutations suggests that some KRAS-WT PDAC cases may arise from genomic instability and epigenetic dysregulation.

(2) Immunotherapy Potential in KRAS-WT PDAC

Higher rates of MSI-H and TMB-H in KRAS-WT tumors indicate potential responsiveness to immune checkpoint inhibitors. MSI-H is a pan-cancer biomarker for immunotherapy approval, while TMB-H also correlates with immunotherapy efficacy. The enriched immune cell infiltration (CD8+ T cells, NK cells, dendritic cells) further supports an immunologically active state in KRAS-WT PDAC, potentially enhancing treatment response.

(3) Application of KRAS WT & cRAF Binding Assay Kits in Mechanistic Studies

Establishing KRAS wild-type status is prerequisite for identifying alternative drivers. However, some KRAS-WT tumors may exhibit non-classical RAS pathway activation mechanisms, such as RAS GTPase-activating protein inactivation or RAS guanine exchange factor overactivation. The Human KRAS WT & cRAF Binding Assay Kit evaluates baseline functional activity of wild-type KRAS protein by measuring its binding to downstream effector cRAF, indirectly reflecting upstream signaling input. Combined with functional assays, this tool helps identify bypass RAS pathway activation in KRAS-WT tumors, advancing understanding of driving mechanisms.

V. Manufacturers Providing Human KRAS WT & cRAF Binding Assay Kits

Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed the "UniOne® TR-FRET Human KRAS WT & cRAF Binding Kit", a high-performance analysis platform specifically designed to study the interaction between wild-type KRAS and downstream effector cRAF. Based on time-resolved fluorescence resonance energy transfer (TR-FRET) technology, this kit enables precise and efficient assessment of binding activity between human wild-type KRAS protein and the cRAF RAS-binding domain (RBD), offering standardized solutions for targeted drug development, KRAS signaling research, and inhibitor screening.

Nanjing UA-Bio Technology Co., Ltd. is dedicated to delivering cutting-edge reagents and tools for immunology, cell therapy, and innovative drug development. For detailed specifications (Catalog No.: UA086033), validation data, or application inquiries regarding the "UniOne® TR-FRET Human KRAS WT & cRAF Binding Kit", please contact us.